<code id='00891A2808'></code><style id='00891A2808'></style>
    • <acronym id='00891A2808'></acronym>
      <center id='00891A2808'><center id='00891A2808'><tfoot id='00891A2808'></tfoot></center><abbr id='00891A2808'><dir id='00891A2808'><tfoot id='00891A2808'></tfoot><noframes id='00891A2808'>

    • <optgroup id='00891A2808'><strike id='00891A2808'><sup id='00891A2808'></sup></strike><code id='00891A2808'></code></optgroup>
        1. <b id='00891A2808'><label id='00891A2808'><select id='00891A2808'><dt id='00891A2808'><span id='00891A2808'></span></dt></select></label></b><u id='00891A2808'></u>
          <i id='00891A2808'><strike id='00891A2808'><tt id='00891A2808'><pre id='00891A2808'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:Wikipedia    Page View:68
          Person wearing a blue glove holding money against a blue backdrop.
          Adobe

          WASHINGTON — Medicare officials are moving forward with a plan to claw back money from certain hospitals to try to remedy overpayments struck down by the Supreme Court, they announced Thursday.

          A federal court ordered the Department of Health and Human Services to compensate hospitals that receive discounted drugs through the 340B program for billions of dollars of underpayments, but the money had already gone out to hospitals that didn’t participate in the program.

          advertisement

          Medicare is planning to send $9 billion in lump-sum payments to more than 1,600 hospitals that participate in the drug discount program after the Supreme Court found the program underpaid them for prescription drugs, the agency announced on Friday.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more
          The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)
          The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Cosmetics set for new safety regulation. Why the industry is on board

          AlbertoPellaschiar/APWASHINGTON—ForthosealreadyfelledbyfumesfromtheBrazilianBlowout,itmightbesmallco